52
Participants
Start Date
January 31, 2002
Primary Completion Date
May 31, 2013
Study Completion Date
May 31, 2013
Melphalan
Arm 1 = 140 mg/m\^2 intravenous over 20 Minutes on Day -1; Arm 2 = 100 mg/m\^2 intravenous over 20 Minutes on Day -1.
Fludarabine
30 mg/m\^2 intravenous daily over 30 Minutes for 4 Days (Beginning Day -4).
Stem Cell Infusion
Stem Cell Infusion on Day 0.
Rituximab
375 mg/m\^2 intravenous on Day -5, +2 +9 and +16.
UT MD . Anderson Cancer Center, Houston
M.D. Anderson Cancer Center
OTHER